X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
Onpattro (patisiran) is a double-stranded siRNA that causes degradation of mutant and wild-type TTR mRNA through RNA interference resulting in reduction of serum TTR protein and TTR protein deposits in tissues. It is being developed for cardiomyopathy of ATTR amyloidosis.
Lead Product(s): Patisiran
Therapeutic Area: Genetic Disease Product Name: Onpattro
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
Onpattro (patisiran) is a double-stranded siRNA that causes degradation of mutant and wild-type TTR mRNA through RNA interference resulting in reduction of serum TTR protein and TTR protein deposits in tissues. It is being developed for cardiomyopathy of ATTR amyloidosis.
Lead Product(s): Patisiran
Therapeutic Area: Genetic Disease Product Name: Onpattro
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
Onpattro (patisiran) is a double-stranded siRNA that causes degradation of mutant and wild-type TTR mRNA through RNA interference resulting in reduction of serum TTR protein and TTR protein deposits in tissues. It is being developed for cardiomyopathy of ATTR amyloidosis.
Lead Product(s): Patisiran
Therapeutic Area: Genetic Disease Product Name: Onpattro
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2023
Details:
Onpattro (patisiran) is a double-stranded siRNA that causes degradation of mutant and wild-type TTR mRNA through RNA interference resulting in reduction of serum TTR protein and TTR protein deposits in tissues. It is being developed for cardiomyopathy of ATTR amyloidosis.
Lead Product(s): Patisiran
Therapeutic Area: Genetic Disease Product Name: Onpattro
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
ONPATTRO (patisiran) is an RNAi therapeutic that is approved in the United States and Canada for the treatment of the polyneuropathy of hATTR amyloidosis in adults. It is designed to target and silence TTR messenger RNA, thereby reducing the production of TTR protein.
Lead Product(s): Patisiran
Therapeutic Area: Genetic Disease Product Name: Onpattro
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
The 12-month findings across a comprehensive set of exploratory endpoints suggest that treatment with Onpattro (patisiran) was associated with favorable impacts on key measures of cardiac stress and injury, NT-proBNP and Troponin I.
Lead Product(s): Patisiran
Therapeutic Area: Genetic Disease Product Name: Onpattro
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2022
Details:
ONPATTRO (patisiran) is an intravenously administered RNAi therapeutic targeting transthyretin (TTR). It is designed to target and silence TTR messenger RNA, thereby reducing the production of TTR protein before it is made.
Lead Product(s): Patisiran
Therapeutic Area: Genetic Disease Product Name: Onpattro
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
ONPATTRO® (patisiran) is an RNAi therapeutic that is approved in the United States and Canada for the treatment of the polyneuropathy of hATTR amyloidosis in adults.
Lead Product(s): Patisiran
Therapeutic Area: Genetic Disease Product Name: Onpattro
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
ONPATTRO® (Patisiran) is an RNAi therapeutic that is approved in the United States and Canada for the treatment of the polyneuropathy of hATTR amyloidosis in adults.
Lead Product(s): Patisiran
Therapeutic Area: Genetic Disease Product Name: Onpattro
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Details:
The distribution agreement is focused on both ONPATTRO® and GIVLAARI®, the first-ever commercialized RNAi therapeutics, as well as another late-stage therapy in development for Primary Hyperoxaluria Type 1.
Lead Product(s): Patisiran
Therapeutic Area: Genetic Disease Product Name: Onpattro
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Taiba Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 08, 2020
Details:
The global competitive grants program aims to inspire patient advocacy groups to develop solutions that address critical unmet needs among the hATTR amyloidosis, acute hepatic porphyria and primary hyperoxaluria type 1 (PH1) rare disease communities.
Lead Product(s): Patisiran
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Alnylam Pharmaceuticals
Deal Size: $0.3 million Upfront Cash: Undisclosed
Deal Type: Funding June 02, 2020
Details:
Partnership with Gen enables Alnylam to extend access to ONPATTRO to patients suffering from hereditary ATTR amyloidosis with polyneuropathy in Turkey.
Lead Product(s): Patisiran
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Alnylam Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
